Advanced Biological Laboratories (ABL) is at the forefront of innovative clinical solutions, particularly with its DeepChek® Whole Genome SARS-CoV-2 Genotyping Assay. This technology is designed to enhance the understanding of SARS-CoV-2 variants, providing critical insights for clinical applications and public health responses. By leveraging genomic data, the assay aids in tracking the evolution of the virus, which is essential for effective treatment strategies and vaccine development. ABL's commitment to advancing clinical diagnostics is evident in its focus on integrating these solutions into existing healthcare frameworks.

In addition to its work on SARS-CoV-2, ABL has expanded its portfolio through the acquisition of Humedics GmbH, a company specializing in liver function measurement. The LiMAx® test, developed by Humedics, offers a non-invasive method for assessing liver function by analyzing exhaled air. This innovative approach allows for rapid and accurate evaluations, enabling healthcare providers to make informed decisions regarding treatment strategies and disease management. The LiMAx® test is already in routine clinical use across numerous leading university hospitals in Europe, demonstrating its effectiveness in diagnosing liver conditions and guiding surgical planning. ABL's strategic acquisition aims to further enhance the application of this technology, ultimately improving patient outcomes in hepatology.

United States

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL acquired all the patents and IP rights from TherapyEdge, Inc. in 2005 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. COVID-19: CE mark (07/2020)

ABL Diagnostics S.A

Company Details